Your session is about to expire
← Back to Search
Treatment for Fabry Disease
N/A
Recruiting
Research Sponsored by Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 2 years
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this research is to collect biological samples (urine) to develop assays for immune biomarkers to possibly in the future be able to screen subjects with Fabry disease and be able to understand better progression of nephropathy in Fabry disease and predict nephropathy in Fabry disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
identify urinary inflammatory biomarkers associated with nephropathy in Fabry disease, Units pg/ml
Secondary study objectives
Identify biomarkers of renal glomerular function, tubular injury and endothelial dysfunction. Units pg/ml
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Find a Location
Who is running the clinical trial?
Lysosomal and Rare Disorders Research and Treatment Center, Inc.Lead Sponsor
8 Previous Clinical Trials
100,296 Total Patients Enrolled
1 Trials studying Fabry Disease
50 Patients Enrolled for Fabry Disease
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger